Hepion Pharmaceuticals, Inc. financial data

Symbol
HEPA, CTRVP on OTC
Location
Edison, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 322% % -11%
Debt-to-equity 77% % -44%
Return On Equity -401% % 17%
Return On Assets -227% % -9.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11,620,317 shares 67%
Common Stock, Shares, Outstanding 11,620,317 shares 67%
Entity Public Float $5,900,000 USD -85%
Common Stock, Value, Issued $1,162 USD 75%
Weighted Average Number of Shares Outstanding, Basic 11,620,317 shares 8547%
Weighted Average Number of Shares Outstanding, Diluted 11,620,317 shares 8547%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $2,616,613 USD -89%
General and Administrative Expense $4,499,512 USD -40%
Operating Income (Loss) $4,756,162 USD 83%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $9,168,419 USD 65%
Income Tax Expense (Benefit) $3,378,274 USD -17%
Net Income (Loss) Attributable to Parent $9,168,419 USD 60%
Earnings Per Share, Basic -11 USD/shares 98%
Earnings Per Share, Diluted -11 USD/shares 98%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current $3,740,240 USD 5.9%
Property, Plant and Equipment, Net $0 USD -100%
Operating Lease, Right-of-Use Asset $0 USD -100%
Other Assets, Noncurrent $66,505 USD
Assets $3,740,240 USD 0.68%
Accounts Payable, Current $77,243 USD -59%
Accrued Liabilities, Current $55,859 USD -82%
Liabilities, Current $347,411 USD -87%
Operating Lease, Liability, Noncurrent $41,248 USD
Liabilities $415,808 USD -90%
Accumulated Other Comprehensive Income (Loss), Net of Tax $8,345 USD
Retained Earnings (Accumulated Deficit) $245,440,771 USD -3.9%
Stockholders' Equity Attributable to Parent $3,324,432 USD 717%
Liabilities and Equity $3,740,240 USD 0.68%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,117,422 USD 69%
Net Cash Provided by (Used in) Financing Activities $5,297,403 USD 186%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 120,000,000 shares 0%
Common Stock, Shares, Issued 11,620,317 shares 67%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4,179,981 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,321,078 USD 55%
Deferred Tax Assets, Valuation Allowance $44,584,134 USD 0.09%
Deferred Tax Assets, Gross $44,584,134 USD -0.05%
Operating Lease, Liability $0 USD -100%
Depreciation $100,000 USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $9,106,243 USD 60%
Lessee, Operating Lease, Liability, to be Paid $139,259 USD -47%
Operating Lease, Liability, Current $117,952 USD 5%
Lessee, Operating Lease, Liability, to be Paid, Year One $97,815 USD -29%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $21,307 USD 3%
Additional Paid in Capital $247,060,568 USD
Current State and Local Tax Expense (Benefit) $3,000,000 USD
Depreciation, Depletion and Amortization $30,758 USD 71%
Share-based Payment Arrangement, Expense $106,658 USD -91%
Interest Expense $11,492 USD 12%